This is a double-blind randomized controlled study. The study will last up to 16 weeks from the initial phone screen (it could take up to eight weeks to schedule and complete the initial screening process and schedule the 2 MRI visits). Once subjects have completed the screening process, they will begin the 8-week trial phase. Subjects will be assessed weekly throughout the study for efficacy and tolerability.
The investigators plan to recruit 80 participants with emotional dysregulation (ED) in the treatment arm. In addition, the investigators will aim to recruit 40age-, sex-, and parental-education matched participants without emotional dysregulation, and major psychopathology as Typically Developing (TD) control participants in the control arm.
Upon scheduling the baseline visit, only the emotional dysregulation (ED) participants will be randomized 1:1 to be exposed to NAC or placebo treatment for 8 weeks. Participants will complete baseline and post-treatment (endpoint) brain MRI acquisition. TD participants will complete the same screening and characterization process as the ED group and then will be invited to complete MRI eligibility screening and to be scanned twice, separated by an eight-week interval, but the TD will not complete the NAC treatment or receive a placebo. See Table 1 (Study Schema) for a complete list of characterization measures to be completed by each group.

Start Date01 Jan 2027

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07543458

/ Not yet recruitingPhase 3IIT

A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)

The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.

Start Date01 Oct 2026

Sponsor / Collaborator

Oxford University Clinical Research Unit, Vietnam

[+8]

NCT06260566

/ Not yet recruitingPhase 1IIT

A Phase 1 Trial of Tolerability of Enteral N-Acetylcysteine in Infants

Biliary atresia (BA) is a neonatal liver disease characterized by impaired bile flow and is the most common indication for pediatric liver transplantation. BA can be treated with the Kasai portoenterostomy (KP), a procedure that attempts to restore bile flow and slow disease progression. However, success of the KP procedure is quite variable, and lack of adjuvant medical therapies following KP is a major gap in pediatric hepatology.
This study begins to explore oral N-acetylcysteine (NAC) as a potential medical therapy in BA by determining whether an oral formulation can be given to infants. The primary objective is to determine tolerability of the oral NAC formulation. The primary outcome is tolerating at least 3 out of 4 total doses without emesis. The Bayesian Optimal Interval Design (BOIN) trial design will be used to determine the maximum tolerated dose of oral NAC. Our secondary objective is to assess palatability of the oral NAC formulation by comparing facial expressions when taking oral NAC versus other medications commonly given to cholestatic infants.

Start Date01 Oct 2026

Sponsor / Collaborator

Baylor College of Medicine

[+1]

100 Clinical Results associated with Acetylcysteine

100 Translational Medicine associated with Acetylcysteine

100 Patents (Medical) associated with Acetylcysteine

28,833

Literatures (Medical) associated with Acetylcysteine

31 Dec 2026·DRUG DELIVERY

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Review

Author: O'neill, Allison F ; Huitema, Alwin D R ; Bleyer, Archie ; Bouffet, Eric ; Streefkerk, Nienke ; Masroor, Amirhossein ; Sullivan, Michael ; Fresneau, Brice ; Maibach, Rudolf ; Van Grotel, Martine ; Hoetink, Alexander E ; Rajput, Kaukab M ; Papadakis, Vassilios ; Knight, Kristin ; Brock, Penelope R ; Geller, James I ; Kogner, Per ; Veal, Gareth J ; Ansari, Marc ; Van Den Heuvel-Eibrink, Marry M

Cisplatin-induced hearing loss (CIHL) in pediatric cancer patients is an irreversible and highly prevalent adverse effect with a devastating impact on quality of life. Sodium thiosulfate (STS) has recently been approved for systemic administration as an otoprotective agent in children. However, implementation of systemic STS has its challenges, and there is currently limited evidence to support local STS for children. This review investigates the potential value of locally administered otoprotective agents other than STS with a focus on future pediatric implementation. We conducted a systematic review on the efficacy and safety of locally applied non-STS otoprotective agents in in vivo settings. This included a summary of investigated drug delivery methods and administration routes. We identified 70 preclinical and eight clinical studies. Agents were categorized based on their biological mechanisms: anti-inflammatory, chemical deactivators, calcium blockers, biologicals, and miscellaneous mechanisms. Preclinical studies investigated 45 different agents. Dexamethasone and N-acetylcysteine were identified as efficacious agents recurrently and progressed to clinical trials. Dexamethasone was investigated in three randomized clinical trials (RCTs) and three non-randomized clinical studies and showed statistically significant but not clinically relevant benefit in two trials. N-acetylcysteine was investigated in two clinical trials and one RCT and was minimally effective in the RCT and in one clinical study. Our review did not identify available studies of local alternative otoprotective agents that could reliably replace systemic STS in terms of safety and efficacy for pediatric patients. Further research on the optimal dosage, delivery method, and timing of otoprotective agents is needed.

31 Dec 2026·CNS oncology

Arginine deprivation induces prolonged autophagy activation and ROS-dependent cell death in glioblastoma multiforme

Article

Author: El-Jawhari, Yasmin ; Saad, Rawan ; Sarieddine, Majd ; El-Husseini, Nour ; El-Sibai, Mirvat ; Shaheen, Maha ; Abi-Habib, Ralph J. ; Abdelkhalek, Maya

BACKGROUND:

Arginine deprivation was shown to be selectively cytotoxic to GBM cells with cell death being caspase-independent, non-apoptotic. In this study, we assess the impact of prolonged arginine deprivation on GBM cells, the potential activation of autophagy, the mechanism of its activation, and its impact on cell cytotoxicity.

METHODS:

GBM cell lines A172 and U251 were used in this study and arginine deprivation was induced by a cobalt-substituted, PEGylated human arginase I [HuArgI (Co)-PEG5000].

RESULTS:

Arginine deprivation induced prolonged cytotoxicity up to 120 hours post-treatment. Cytotoxicity persisted despite cells overexpressing ASS-1. Arginine deprivation also induced a marked and sustained activation of autophagy, starting at 24 hours and lasting up to 120 hours post-treatment. Autophagy was shown to induce cell death since its inhibition by chloroquine significantly decreased cytotoxicity, indicating that the extensive activation of autophagy is resulting in cell death of GBM cells. Moreover, ROS was shown to accumulate in treated cells and neutralizing ROS using NAC did not affect the autophagic response but led to a complete reversal of cytotoxicity, demonstrating that death by autophagy is dependent on ROS generation.

CONCLUSION:

Arginine deprivation leads to sustained activation of autophagy and subsequent ROS-dependent cell death in GBM cells.

31 Dec 2026·Journal of the International Society of Sports Nutrition

A comprehensive review of the physiology and evidence base to guide the use of ergogenic and medical supplements for enhanced cycling performance

Review

Author: Edwards, Sophie ; Cornelisse, Erik ; Prieto-Bellver, Gorka ; Rowland, Angela ; Rowland, Andrew ; Hopkins, Ashley M ; Karapetis, Christos S ; Menz, Bradley ; Wallen, Matthew P

BACKGROUND:

A growing body of evidence supports the use of supplements to enhance cycling performance through both direct and indirect mechanisms.

METHODS:

This review was informed by a structured literature search conducted in PubMed, Scopus and Web of Science for peer-reviewed studies published up to May 2025. Studies were included if they involved human participants, were published in English and evaluated outcomes related to endurance performance, recovery or physiological function.

RESULTS:

Direct enhancement with ergogenic supplements is primarily achieved via modulation of skeletal muscle energy metabolism. During exercise, adenosine triphosphate (ATP) resynthesis is driven by the phosphagen system, glycolysis, oxidative phosphorylation and beta-oxidation, with each system contributing according to the intensity and duration of the effort. Supplements such as beta-alanine, caffeine, carbohydrates, carnitine, creatine monohydrate, dietary nitrates, electrolytes, exogenous ketones, N-acetylcysteine and sodium bicarbonate support these energy systems by improving substrate utilization, buffering capacity, energy availability or resistance to fatigue. In addition to ergogenic supplements that directly enhance performance, medical supplements play an important indirect role by supporting bone health, connective tissue integrity, inflammation management, micronutrient status, muscle repair and gut function. Evidence-based options for cyclists include calcium, cherry juice, collagen, curcumin, iron, multivitamins, omega-3 fatty acids, pickle juice, probiotics, protein, vitamin C, vitamin D and zinc. Each contribute to either improved recovery, immune support or long-term physiological adaptation. Evidence quality varied substantially across supplements, with strongest support for Australian Institute of Sport (AIS) Group A compounds. The integration of physiological testing including assessments of maximal oxygen consumption (VO₂max), lactate threshold, metabolic substrate utilization and blood biomarkers may inform the development of individualized supplementation strategies tailored to training demands and competitive goals.

CONCLUSIONS:

This evidence-informed approach underscores the synergistic relationship between nutrition, training and performance optimization in cycling. Future research should explore personalized nutrition frameworks, interactions between multi-supplement protocols and the molecular mechanisms underpinning adaptation to endurance training and nutritional interventions.

132

News (Medical) associated with Acetylcysteine

24 Jun 2026

·www.prnewswire.com

Roamin Cat Should Have Held the Onions

Frisky Feline Poisoned by Discarded Sliders MINNEAPOLIS, June 24, 2026 /PRNewswire/ -- Sometimes a pet is named for his appearance, such as Spot or Red. Others practically name themselves by their behavior. From the moment Michael Nihart saw his new cat investigating the entire house, it was pretty clear that Roamin had his name, and that he likes mischief. "He's like a dog in a cat's body," joked Lisa Nihart, Michael's mom. "He's always getting into trouble and trying to sneak outside." Continue Reading "Cats often have very high curiosity, which in this case could have actually killed him." Post this Roamin found out the hard way how dangerous ingesting onions are for cats. That curious nature, however, can get pets into trouble. "Cats often have very high curiosity, which in this case could have actually killed him," said Dr. Renee Schmid, a senior veterinary toxicologist and director of Veterinary Medicine at Pet Poison Helpline. "Roamin got into the trash and ingested two White Castle™ sliders with diced onion. Although the high fat and salt content can cause gastrointestinal upset, it was the onions that caused us the most concern." In honor of National Onion Day on June 27, the toxicology experts at Pet Poison Helpline want to warn pet lovers that toxic doses of onions by pets can result in oxidative damage to the red blood cells, making the cells more likely to rupture. It can also cause gastroenteritis, resulting in nausea, oral irritation, drooling, abdominal pain, vomiting and diarrhea. With onions, poisoning may have a delayed onset, and clinical signs may not be apparent for several days. Left untreated, it can result in death. "Not only do White Castle sliders have onions on them, but they also have onions in them," Lisa Nihart explained. "Being a veterinary technician, I knew onions were dangerous to cats, so I called Pet Poison Helpline. They recommended I take Roamin to the hospital." Roamin was taken to Wellhaven Pet Health Maple Grove for evaluation and treatment. "Nobody had any idea what to do," Lisa Nihart said. "It's a good thing we already had a case started with Pet Poison Helpline, because the hospital team was able to begin evaluating her immediately. Because I'm a tech, I thought I could monitor and treat him at home." Based on the timing of the ingestion, it was too late to induce vomiting or provide additional decontamination, so an anti-emetic was given, bloodwork was performed and subcutaneous fluids were administered. Nihart decided to take Roamin home and was given antioxidants to administer to help minimize red cell damage and advised to recheck bloodwork every two to three days to evaluate for anemia. Roamin would also need to return the veterinary hospital if he was lethargic, not eating, or had any other abnormal behavior. After several days, Michael noticed that Roamin was still not his normal rambunctious self and had pale coloring to his gums, which could indicate anemia. He insisted that something was wrong, and his mom took the cat back to the hospital for a recheck of his bloodwork and potentially additional treatment. By that time, Roamin's blood cells were showing signs of significant damage. Roamin's red blood cell count was dangerously low, and his bloodwork was consistent with red blood cell damage caused by the toxic components of onions. "We recommended a very aggressive treatment," Dr. Schmid said. "One of our veterinary toxicologists who managed Roamin's case advised to start intravenous fluids, an additional antioxidant and glutathione replacer called N-Acetylcysteine, as well as additional antioxidants. Fortunately for Roamin, he remained stable enough to not need a blood transfusion." Roamin remained in the hospital for several days and continued to have bloodwork monitoring for two weeks to ensure his red blood cells had returned to normal, healthy numbers. While Roamin's exposure had a happy ending, onion poisoning, and any Allium species in general, be challenging to relay the potential severity with pet owners. Many pet foods and products contain onion or garlic to enhance flavoring. When it comes to determining the toxicity of garlic and onions, the dose matters. The amounts added to pet products are well below a dose where poisoning could occur, but that doesn't mean those foods aren't toxic at larger doses. Also, because signs of poisoning often do not develop until several days to a week after the ingestion, many pet owners will assume their pet is out of the woods and may choose not to be more aggressive with their initial care. Unfortunately, this can result in fatal consequences. "I'm really glad Michael is so focused on Roamin," Lisa Nihart added. "He noticed the changes in his behavior and talked me into going back to the hospital. It probably saved Roamin's life." Pet Poison Helpline created Toxin Tails to educate the veterinary community and pet lovers on the many types of poisoning dangers facing pets, both in and out of the home. All the pets highlighted in Toxin Tails have been successfully treated for the poisoning and fully recovered. About Pet Poison Helpline Pet Poison Helpline®, your trusted source for toxicology and pet health advice in times of potential emergency, is available 24 hours, seven days a week for pet owners and veterinary professionals who require assistance treating a potentially poisoned pet. Per incident and subscription service options are available. We are an independent, nationally recognized animal poison control center triple licensed by the Boards of Veterinary Medicine, Medicine and Pharmacy providing unmatched professional leadership and expertise. Our veterinarians and board-certified toxicologists provide treatment advice for all species, including dogs, cats, birds, small mammals, large animals and exotic species. As the most cost-effective option for animal poison control care, Pet Poison Helpline's fee of $89 per incident includes follow-up consultations for the duration of the case. The company also offers pethelpline(SM) and pethelplinePRO(SM) subscription services directly to pet lovers. Based in Minneapolis, Pet Poison Helpline is available in North America by calling 800-213-6680. Additional information, including a chat feature for pet owners, can be found online at . Contact: Curtis Steinhoff Pet Poison Helpline® (602) 300-8466 [email protected] SOURCE Pet Poison Helpline 21% more press release views with Request a Demo

28 May 2026

·www.prnewswire.com

Nevisense detects skin barrier damage by chemicals used in household cleaning products in a new ex-vivo study

STOCKHOLM, May 28, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB) , a leader in AI-based devices for detection and prevention in dermatology, announced today the publication of a scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to show that surfactants in household cleaning products disrupt the human skin barrier. In the study, human ex vivo skin samples were exposed to Sodium dodecyl sulfate (SDS), a surfactant in household cleaning products which is known to impair the barrier. Also, skin that was affected by SDS were treated with N-acetylcysteine (NAC) and nicotinamide (NAM) to promote recovery of skin barrier function. Nevisense was used in the study to detect the changes in the skin barrier and detected that short-term exposure to SDS rapidly disrupts human skin barrier integrity within minutes as well as the effect of NAC and NAM. Skin barrier research is an expanding area in dermatology. Disruption of skin barrier function plays a key role in the development and severity of e.g. contact dermatitis from chemical substances "We are happy to see that Nevisense and EIS-technology continue to provide value in this type of research. This study further strengthens the role of Nevisense as an effective research device and show the potential to become the state-of-the-art research tool within the skin barrier research," said Pia Renaudin, CEO of SciBase. The full results of the study have now been published in the scientific journal Allergy " Rapid Human Skin Barrier Disruption by Sodium Dodecyl Sulfate and Associated Molecular Mechanisms," - Li - Allergy, DOI: For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected] Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected] About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at . For press releases and financial reports visit: This information was brought to you by Cision The following files are available for download: 21% more press release views with Request a Demo

05 May 2026

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders' equity. "We entered 2026 with strong momentum following an outstanding 2025, which featured double-digit revenue growth, the addition of a new product to our portfolio, new international approvals and breakthrough clinical study results," said A.J. Kazimi, Cumberland Pharmaceuticals CEO. "We have built on that momentum through our recently announced Strategic Transaction, which represents an important next step in our Company's evolution, enabling us to sharpen our focus on developing high-value product candidates, while unlocking significant value for our shareholders." RECENT COMPANY DEVELOPMENTS INCLUDE: Strategic Transaction Cumberland recently announced a Strategic Transaction with Apotex Inc., the largest Canadian-based pharmaceutical company, to integrate the branded U.S. commercial businesses. Under the terms of the agreement, Apotex will acquire Cumberland's portfolio of FDA-approved brands for $100 million in cash consideration, subject to Cumberland shareholders' approval and certain other customary closing conditions. This transaction is designed to unlock value and sharpen Cumberland's focus on advancing its pipeline of differentiated product candidates designed to address unmet medical needs. The integration of Cumberland's products will create more critical mass to support patient care and expand product distribution. Following the closing of the transaction, Cumberland will retain its development programs, as well as its majority ownership in Cumberland Emerging Technologies. This positions Cumberland to operate with the profile of an innovative, development-stage biopharmaceutical organization devoted to new medicines for the future. Development Pipeline In addition to its portfolio of FDA-approved brands involved in the transaction with Apotex, Cumberland is developing ifetroban, a potent thromboxane antagonist, through a series of clinical programs designed to address unmet medical needs with significant market potential. Cumberland has announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. Discussions with the FDA are underway regarding the study results and remaining requirements for approval. During the first quarter of 2026, the FDA granted Fast Track Designation for Cumberland's ifetroban candidate product for DMD patients. This designation is intended to accelerate the development and review of therapies that address serious conditions with unmet medical needs. Importantly, it allows for more frequent FDA interaction, rolling data submissions and earlier guidance throughout the approval process. The program previously received both Orphan Drug and Rare Pediatric Disease designations from the FDA. In addition, Cumberland has a Phase II clinical program evaluating its ifetroban product candidate in patients with Systemic Sclerosis ("SSc") or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs. Enrollment in the study is completed and the next milestone will be announcing its top-line study results. Cumberland's third development program involves the use of ifetroban in patients with Idiopathic Pulmonary Fibrosis ("IPF"), the most common form of progressive fibrosing interstitial lung disease. Enrollment in the study is well underway at medical centers across the U.S., with interim safety and interim efficacy results pending. FINANCIAL RESULTS: Net Revenue: For first quarter of 2026, the Company's net revenues of $9.1 million, which represented a 5% increase compared to the first quarter of 2025 after removing the $3 million milestone payment last year associated with the approval of Vibativ® in China. Cumberland's branded portfolio revenue included $1.0 million for Kristalose®, $2.9 million for Sancuso®, $2.1 million for Vibativ®, $1.0 million for Caldolor® and $1.9 million for Talicia.® Operating Expenses: Total operating expenses for the quarter were $12.3 million. Net Income (Loss): The net loss for the first quarter of 2026 was approximately $3.3 million. Adjusted Earnings (Loss): Adjusted loss for the quarter was $1.9 million, or $0.13 per share. Balance Sheet: At March 31, 2026, Cumberland had approximately $71.0 million in total assets, including $11.0 million in cash and cash equivalents. Liabilities totaled $49.7 million, including $5.2 million on the company's credit facility. Total shareholders' equity was $21.6 million on March 31, 2026. EARNINGS REPORT CALL: A conference call will be held today, May 5, 2026, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results. The link to register is . Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting: . ABOUT CUMBERLAND PHARMACEUTICALS: Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote ® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor ® (ibuprofen) injection, for the treatment of pain and fever; Kristalose ® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso ® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol ® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia ® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis and Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company's website at . About Acetadote ® (acetylcysteine) Injection Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit . About Caldolor ® (ibuprofen) Injection Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit . About Kristalose ® (lactulose) Oral Solution Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit . About Sancuso ® ( granisetron) Transdermal System Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient's bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit . About Vaprisol ® (conivaptan hydrochloride) Injection Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit . About Vibativ ® (telavancin) for Injection Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit . About Talicia ® Talicia® is an FDA approved oral capsule for the treatment of Helicobacter pylori (H. pylori) infection in adults, a bacterial infection of the stomach and leading risk factor for gastric cancer. Talicia is listed as a first line option in the 2024 ACG Guideline for the treatment of H. pylori and features three key advantages: 1) high eradication rates - >90% in confirmed adherent patients, 2) the simplicity of an all-in-one capsule, and 3) low resistance to the two antibiotics - amoxicillin and rifabutin. For more information, please visit . FORWARD LOOKING STATEMENTS: This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "goal", "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include risks and uncertainties related to the strategic transaction, risks related to our ability to develop our pipeline of new product candidates, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the Company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others. Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release. Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include: depreciation, amortization of intangible and right-of-use assets, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance. The Company defines these supplemental financial measures as follows: Adjusted Earnings (loss): Net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense. (a) Represents the share-based compensation of Cumberland. (b) Represents the straight line reduction in carrying value of right-of-use assets. Adjusted Diluted Earnings (loss) Per Share: Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding. SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

Phase 2Drug ApprovalOrphan DrugAcquisitionFast Track

100 Deals associated with Acetylcysteine

External Link

KEGG	Wiki	ATC	Drug Bank
D00221	Acetylcysteine	V03AB23 S01XA08 R05CB01	DB06151

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchitis	China	Parexel China Co.,Ltd.	13 May 2025
Nails, Ingrown	Japan	Maruho Co., Ltd.	27 Mar 2023
Acetaminophen overdose	Australia	Pfizer Australia Pty Ltd.	17 Jul 2006
Pulmonary Disease, Chronic Obstructive	China	Jiangsu Jibeier Pharmaceutical Co. Ltd.	01 Jan 1985
Asthma	Japan	Sannova KK	05 Jan 1965
Bronchiectasis	Japan	Sannova KK	05 Jan 1965
Bronchitis, Chronic	Japan	Sannova KK	05 Jan 1965
Cystic Fibrosis	Japan	Sannova KK	05 Jan 1965
Laryngitis	Japan	Sannova KK	05 Jan 1965
Pharyngitis	Japan	Sannova KK	05 Jan 1965
Pneumonia	Japan	Sannova KK	05 Jan 1965
Pulmonary Emphysema	Japan	Sannova KK	05 Jan 1965
Pulmonary Tuberculosis	Japan	Sannova KK	05 Jan 1965
Chemical and Drug Induced Liver Injury	United States	Apothecon LLC	14 Sep 1963
Liver Injury	United States	Apothecon LLC	14 Sep 1963

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Bronchitis	Phase 3	China	Zambon SpA	21 Jun 2019
Acute Bronchitis	Phase 3	China	Zambon Switzerland Ltd.	21 Jun 2019
Idiopathic Pulmonary Fibrosis	Phase 3	Belgium	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	France	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Germany	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Italy	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Netherlands	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	Spain	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	United Kingdom	Zambon SpA	01 Mar 2000
Common Cold	Phase 2	Canada	Novartis AG	01 Jan 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03822637 (ENACT, CTgov)	Phase 4	Asthma	4	N-Acetylcysteine (NAC) (20% N-Acetylcysteine (NAC))	axwhkuawov(cajbqcdlfu) = cthbwoeenk sctyjxhiwz (uszehspuif, 3.74) View more	-	11 Jun 2026
				Placebo+NAC+albuterol (Placebo)	axwhkuawov(cajbqcdlfu) = srychbiabh sctyjxhiwz (uszehspuif, 6.49) View more
NCT04481048 (DoDNAC, CTgov)	Phase 2	Neurofibromatosis 1	25	N-Acetyl cysteine (N-Acetylcysteine (NAC))	jzgpdyvxkk(wtiwvxnppz) = khjuwcldbe kskvdkdbqh (ptxkxsfduc, 9.3) View more	-	05 Jun 2026
				Placebo (Placebo)	jzgpdyvxkk(wtiwvxnppz) = aaurxhsfqm kskvdkdbqh (ptxkxsfduc, 12.7) View more
NCT03220776 (Pubmed \| Transl Psychiatry)	Phase 2	Alcohol Use Disorder	54	N-acetylcysteine (NAC)	igmsnibxei(bvysikmomt) = lhbeuxbsvl zbtwxekiih (pcrfomvgdz, 4.6) View more	Positive	03 Jun 2026
				Placebo	igmsnibxei(bvysikmomt) = verbzijgwa zbtwxekiih (pcrfomvgdz, 4.55) View more
NCT06581783 (Pubmed \| J Gastroenterol Hepatol)	Not Applicable	-	1,200	Placebo	clqpyeslwt(ljiazbxmts) = stgmyjwksc uyapktbhdd (uqygxkxpxc ) View more	Positive	10 Apr 2026
				Simethicone + NAC (premedication to endoscopy interval of 10-20 min)	clqpyeslwt(ljiazbxmts) = gzgiienssi uyapktbhdd (uqygxkxpxc ) View more
NCT03911414 (CTgov)	Phase 4	Dietary Supplement \| Depressive Disorder \| Emotional lability ... View more	27	Omega-3 Fatty Acids+Inositol (Omega-3 Fatty Acids + Inositol)	hpfvixnkia(dzlevbpgcc) = mgyubdqxbj ifvstcarqg (sxwsquvmfh, 5.5) View more	-	18 Mar 2026
				Open-label Treatment with N-acetylcysteine (N-acetylcysteine)	hpfvixnkia(dzlevbpgcc) = vfnqhlzhhm ifvstcarqg (sxwsquvmfh, 5.9) View more
NCT05944458 (Pubmed \| Environ Toxicol Pharmacol)	Phase 4	Thrombocytopenia	250	N-acetylcysteine (IV NAC) 600 mg	owjfmmzbwa(vxtsyjqdrm) = pdvcmynvxo rvzhmpbxas (ywfpaxnxvw ) View more	Positive	01 Mar 2026
				Placebo	owjfmmzbwa(vxtsyjqdrm) = rkztsxkdbo rvzhmpbxas (ywfpaxnxvw ) View more
NCT04013555 (TrypNAC-II, CTgov)	Phase 1/2	Schizoaffective disorder \| Schizophrenia	88	Tryptophan+N-acetylcysteine (NAC) (N-acetylcysteine & Tryptophan)	ypxuegqcbn(sxrcorqbxu) = rndnaennlw xpjrtzjfns (gatclayuby, 1.89) View more	-	11 Feb 2026
				Placebo+Tryptophan (Placebo & Tryptophan)	ypxuegqcbn(sxrcorqbxu) = dyfcfgalnl xpjrtzjfns (gatclayuby, 1.22) View more
NCT04155632 (COCA, CTgov)	Phase 2	Cocaine-Related Disorders	32	cTBS (Active Theta Burst Stimulation)	bsvwtivduv(rozlirjgln) = kswqvkalqn jokpchhapo (wcjtzjfard, 0.0080) View more	-	24 Sep 2025
				cTBS (Sham Theta Burst Stimulation)	bsvwtivduv(rozlirjgln) = cqvbcakioz jokpchhapo (wcjtzjfard, 0.0105) View more
NCT03707951 (Pubmed \| J Am Acad Child Adolesc Psychiatry)	Phase 2	Alcohol Use Disorder	126	N-acetylcysteine 2400 mg/day	feeeeznahw(omyetikies) = N-acetylcysteine did not significantly reduce alcohol use compared to placebo. lfzwzbdfqd (cnhvbdradd ) View more	Positive	01 Sep 2025
				Placebo
NCT06024031 (Pubmed \| Cancer Lett)	Phase 2	Acute Myeloid Leukemia reactive oxygen species (ROS)	30	N-acetyl-L-cysteine	xbjsoozoku(lfzlbtxnlh) = iadvpxkaus segqblpeqe (jtmzlugylr ) View more	Positive	01 Aug 2025
				N-acetyl-L-cysteine (Control Group)	xbjsoozoku(lfzlbtxnlh) = ezaqjkzpbp segqblpeqe (jtmzlugylr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis